Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




AI Predicts Short-Term Risk of Atrial Fibrillation Using 24-Hour Holter Recordings

By HospiMedica International staff writers
Posted on 22 Jun 2022

Atrial Fibrillation (AFib) affects millions of people each year. More...

However, the condition is often unrecognized and untreated. Nowadays, patients are subject to 24-hour ambulatory electrocardiograms (ECGs) to receive a diagnosis, but this short-duration recording is known to have a low diagnostic yield and misses many patients with infrequent AFib episodes. Now, a first-of-its-kind study has demonstrated the capability of artificial intelligence (AI) in predicting AFib in the short-term using 24-hour Holter compared to resting 12-lead ECGs. While 12-lead ECG gives access to a larger view of the hearts' activity for a short period, 24-hour Holter provides longer-duration signals, therefore, offering additional inputs for predicting models.

The study consisted of training Cardiologs’ (Paris, France) deep neural network to predict the near-term presence or absence of AFib by only using the first 24 hours of an extended Holter recording. Results showed that the network was able to predict whether AFib would occur in the near future with an area under the receiver operating curve, sensitivity, and specificity of 79.4%, 76%, and 69%, respectively, and outperformed ECG features previously shown to be predictive of AFib. These results showed a 10-point improvement compared to a baseline model using age and sex.

"Cardiologs' study shows that 24-hour Holter data can be used to enhance current monitoring capabilities, bringing hope to high-risk patients who would benefit from proactive treatment and AFib mitigation strategies," said Dr. Jagmeet Singh, Cardiologist at Massachusetts General Hospital (MGH) and Professor of Medicine at Harvard Medical School, who led the study. "By getting patients the care they need sooner and potentially preventing more severe outcomes, we could help save many lives."

"The extension of AI capabilities towards predictions and digital biomarkers has the potential to bring improved health outcomes leading to new diagnostic paradigms," added Cardiologs CEO and co-founder Yann Fleureau. "Predictive biomarkers may lead to early detection, optimized patient monitoring, and improved patient management in general. At Cardiologs, we are excited to be at the forefront of innovations that help set a new standard of patient care."

Related Links:
Cardiologs


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.